Company Overview and News

4
Achillion Appoints Dr. Steven Zelenkofske as Chief Medical Officer and Further Strengthens Clinical Development Team

20h globenewswire - 1
NEW HAVEN, Conn., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. Dr. Zelenkofske will assume responsibility for the clinical development of Achillion’s oral factor D small molecule portfolio of compounds to treat complement-mediated diseases.
SGYP BSX SGYPW ACHN

3
Synergy Pharmaceuticals Appears To Be Back On Track At Last

2018-08-20 seekingalpha
Synergy has faced the daunting task of commercializing constipation drug Trulance via a risky go-it-alone strategy; initial efforts were ruinously expensive and yielded anemic prescription growth.
SGYP IRWD SGYPW SLUXF

11
Ironwood Pharmaceuticals' Proposed Separation Should Offer A Favorable Outcome For Shareholders

2018-08-17 seekingalpha - 1
Ironwood Pharmaceuticals is a commercial biotechnology company focused on the treatment of gastrointestinal diseases, abdominal pain, and gout.
IRWD SGYP BIIB AGN AZN SGYPW SCMP SNY

7
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

2018-08-14 zacks - 1
On Aug 13, we issued an updated research report on Ironwood Pharmaceuticals, Inc. (IRWD - Free Report) . This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of treatments primarily addressing gastrointestinal (“GI”) diseases. The company’s sole marketed drug, Linzess, is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (“CIC”).
4503 IRWD SGYP ALPMY AZN AGN ALPMF AZN SGYPW

2
Synergy Has Turned A Corner

2018-08-13 seekingalpha - 2
Before this quarter I had projections for SGYP to run out of money in Q4 2019.
SGYP SGYPW

4
Synergy Pharmaceuticals (SGYP) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks - 3
Synergy Pharmaceuticals (SGYP - Free Report) just came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.
SGYP KRO CIVI SGYPW SBOW

17
Achaogen: Worth A Look At $7 Though Risks Persist

2018-08-01 seekingalpha - 3
Shares of Achaogen have dropped approximately 44% from the $13 level prior to FDA PDUFA date.
SGYP SGYPW AKAO

4
Is the Options Market Predicting a Spike in Synergy Pharmaceuticals (SGYP) Stock?

2018-07-27 zacks - 3
Investors in Synergy Pharmaceuticals Inc. (SGYP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 19, 2018 $1 Put had some of the highest implied volatility of all equity options today.
SGYP SGYPW TPH NVR TRN

135
Synergy: Can It Come Back?

2018-07-17 seekingalpha - 2
Synergy (SGYP) has been one of my of my most exasperating investments. I started small and wary last April when I wrote my first exploratory article. I doubled down several times and came to regret each one.
SGYP RAD SGYPW CIC

8
Radius Health Strengthens Senior Management Team with Appointment of Chhaya Shah as Senior Vice President of Technical Operations

2018-07-16 globenewswire - 1
WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations.
ABT SGYP SGYPW RDUS ABT

0
Synergy Pharmaceuticals: Partner, Merger, Ex-USA Deal Or Co-Promotion?

2018-07-13 seekingalpha
On or before August 9th Synergy Pharmaceuticals has committed to provide an update on their strategic business review.
SGYP SGYPW

4
Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options

2018-07-06 zacks - 3
Investors in Synergy Pharmaceuticals Inc. (SGYP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $3.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
SGYP SGYPW ENPH

282
Time Is Nearly Up For Adamis

2018-06-19 seekingalpha - 8
It has now been a year since the FDA approved Adamis' Symjepi epinephrine injector and still, no commercial partner has been confirmed.
SGYP SGYPW ADMP

245
Activist Group Strikes Down Key Proposals At Synergy Pharma

2018-06-18 seekingalpha - 5
The collective activist group who controls more than 13% of the public float proved to be key in striking down shareholder unfriendly proposals.
SGYP SGYPW

309
Synergy Pharmaceuticals: At Last A Glimmer Of Hope?

2018-06-18 seekingalpha - 1
Shareholders voted against the current board; they also voted down several proposals, including one to increase executive compensation and another that would have increased the number of authorized shares.
SGYP AGN SGYPW

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 871639118